Related Experiment Video
Updated: Aug 11, 2026

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
Published on: March 1, 2022
Growth hormone in inflammatory bowel disease
B De Pascalis1, A Bianchi, M A Satta
1Department of Internal Medicine, Catholic University, Rome, Italy.
Growth hormone resistance in inflammatory bowel disease (IBD) is linked to inflammation and undernutrition. Anti-TNF-alpha therapy may reverse this resistance, offering a new therapeutic avenue for IBD patients.
Area of Science:
- Gastroenterology
- Endocrinology
- Immunology
Background:
- Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, involves chronic inflammation and catabolism.
- The growth hormone/insulin-like growth factor-I axis plays a crucial role in IBD by influencing epithelial cell kinetics, collagen deposition, and immunomodulation.
- Growth hormone has demonstrated therapeutic potential in IBD, but acquired resistance is a significant challenge.
Purpose of the Study:
- To investigate the mechanisms of acquired growth hormone resistance in IBD.
- To explore the role of proinflammatory cytokines, such as TNF-alpha and interleukin-6, in mediating this resistance.
- To evaluate the potential of anti-TNF-alpha therapy to reverse growth hormone resistance in IBD.
Main Methods:
- Review of existing clinical and in vivo data on growth hormone axis in IBD.
- Analysis of the impact of proinflammatory cytokines on growth hormone resistance.
- Assessment of infliximab's effect on cytokine levels and growth hormone resistance.
Main Results:
- Acquired growth hormone resistance in IBD is associated with undernutrition and active inflammation.
- Proinflammatory cytokines, particularly TNF-alpha and interleukin-6, are implicated as mediators of growth hormone resistance.
- Anti-TNF-alpha therapy, such as infliximab, effectively reduces cytokine levels and has shown potential to reverse growth hormone resistance in vivo.
Conclusions:
- Growth hormone resistance in IBD is a complex issue influenced by inflammation and nutritional status.
- Targeting TNF-alpha with monoclonal antibodies represents a promising strategy to overcome growth hormone resistance in IBD patients.
- Further research into anti-TNF-alpha therapy could lead to improved treatment outcomes for inflammatory bowel disease.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

